Search alternatives:
greatest decrease » greater decrease (Expand Search), treatment decreased (Expand Search), greater increase (Expand Search)
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
mean decrease » a decrease (Expand Search)
greatest decrease » greater decrease (Expand Search), treatment decreased (Expand Search), greater increase (Expand Search)
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
mean decrease » a decrease (Expand Search)
-
13021
-
13022
Decrease of <i>mlf</i>, <i>cwp1-3</i>, <i>myb2</i>, <i>wrky</i>, <i>pax1</i>, and <i>cdk2</i> gene expression by MLF knock down during encystation using strategy 1.
Published 2019“…Fold change is calculated as the ratio of the difference between MLFko cell line and the control cell line, to which a value of 1 was assigned. Results are expressed as mean ± SD. …”
-
13023
-
13024
Table 1_Genetic susceptibility to gestational diabetes and its mild modification by bisphenol A and thyroid-stimulating hormone: findings from a South Chinese pregnancy cohort.docx
Published 2025“…The protective effect ofPPARGC1A rs8192678 in GDM was confirmed and was non-linearly modified by sqrt-BPA levels. …”
-
13025
Presentation 1_Genetic susceptibility to gestational diabetes and its mild modification by bisphenol A and thyroid-stimulating hormone: findings from a South Chinese pregnancy coho...
Published 2025“…The protective effect ofPPARGC1A rs8192678 in GDM was confirmed and was non-linearly modified by sqrt-BPA levels. …”
-
13026
Image 1_Genetic susceptibility to gestational diabetes and its mild modification by bisphenol A and thyroid-stimulating hormone: findings from a South Chinese pregnancy cohort.pdf
Published 2025“…The protective effect ofPPARGC1A rs8192678 in GDM was confirmed and was non-linearly modified by sqrt-BPA levels. …”
-
13027
Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada
Published 2017“…A higher median income (aOR: 0.83, 0.77–0.89) and higher percentage of those with aboriginal ancestry (aOR: 0.85, 0.76–0.95) were census tract-level sociodemographic covariates associated with decreased access to DRT. …”
-
13028
-
13029
Validation of DEGs in UVA-irradiated S cells that are involved in skin senescence.
Published 2018“…<p>(A) KEGG analysis shows the list of DEGs involved in Toll-like receptor signaling pathway. …”
-
13030
Relationship between infection and immunity.
Published 2025“…Antibody response is greatest against the strain of infection (antigenic distance = 0) and decreases linearly with antigenic distance against other strains. …”
-
13031
-
13032
cART treatment of SweAPP N2a cells promotes mitochondrial dysfunction.
Published 2014“…We found a significant decrease in ATP levels in cells treated with EFV or 3TC/AZT/EFV (***<i>P</i><0.001). …”
-
13033
-
13034
-
13035
MRP3 silencing led to reduce excretion rates and increase intracellular demethoxycurcumin-<i>O</i>-glucuronides in HeLa1A1 cells.
Published 2019“…<p>(A) MRP3 transporter silencing inhibited the accumlated demethoxycurcumin-<i>O</i>-glucuronides (G1) in extracellular medium; (B) MRP3 transporter silencing decreased the excreted demethoxycurcumin-<i>O</i>-glucuronides (G2) in extracellular solution; (C) MRP3 silencing significantly reduced the excretion rates of G1 and G2; (D) MRP3 silencing resulted in evaluation of intracellular G1 and G2 levels; (E) MRP3 silencing decreased total cellular glucuronidation (G1 ang G2) of demethoxycurcumin; (F) Effects of gene silencing on the protein level of MRP3. …”
-
13036
Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Published 2016“…The onabotulinumtoxinA-treated groups had a significantly decreased mean number of urinary incontinence episodes per week (at week 6) (onabotulinumtoxinA200U: MD: -10.72, 95% CI: -13.4 to -8.04, P<0.00001; 300 U: MD: -11.42, 95% CI: -13.91 to -8.93, P<0.00001), MDP (200 U: MD: -33.46, 95% CI: -39.74 to -27.18, P<0.00001; 300 U: MD: -31.72, 95% CI: -37.69 to -25.75, P<0.00001), and greater increased MCC (200 U: MD: 141.30, 95% CI: 121.28 to 161.32, P<0.00001; 300 U: MD: 151.39, 95% CI: 130.43 to 172.34, P<0.00001) compared to the placebo-treated groups. …”
-
13037
-
13038
Transporter inhibitor MK571 inhibited the generation and excretion of demethoxycurcumin-<i>O</i>-glucuronides in HeLa1A1 cells.
Published 2019“…<p>(A) MK571 (5 and 20 μM) inhibited the excretion of demethoxycurcumin-<i>O</i>-glucuronides (G1) in extracellular medium; (B) Inhibitory effects of MK571 (5 and 20 μM) on the excretion of demethoxycurcumin-<i>O</i>-glucuronides (G2) in extracellular solution; (C) MK571 (5 and 20 μM) decreased the efflux excretion rates of G1 and G2; (D) MK571 (5 and 20 μM) evaluated the intracellular levels of G1 and G2; (E) MK571 (5 and 20 μM) reduced the overall formation (<i>f</i><sub>met</sub>) of G1 and G2 in HeLa1A1 cell; The concentration of demethoxycurcumin was 4 μM. …”
-
13039
-
13040